Non-Small Cell Lung Cancer Coverage from Every Angle

Early Research of Birabresib in Lung Cancer and Other Solid Tumors

By: Melissa E. Fryman, MS
Posted: Monday, December 17, 2018

In a phase Ib trial, Christophe Massard, MD, PhD, of the Institut Gustave Roussy, Villejuif, France, and colleagues found that the first-in-class drug birabresib (MK8628/OTX015), a bromodomain inhibitor, has dose proportional exposure, rapid absorption, and a favorable toxicity profile. In fact, clinical activity was reported for a select patient population. For future phase II testing in solid tumors, the authors a dose of 80 mg once a day with continuous dosing. These results were published in the Journal of Clinical Oncology.

In this multicenter, nonrandomized, open-label trial, 46 patients with various tumor types received birabresib. A total of 10 patients had non–small cell lung cancer; in addition, there were 26 patients with castration-resistant prostate cancer and 10 patients with nuclear protein in testis midline carcinoma. They were started at 80 mg once daily continuously (cohort A) or 100 mg for 7 consecutive days (cohort B) in 21-day cycles with parallel dose escalation. Patients received a median of three 21-day cycles.

Dose limiting toxicities occurred in 21% of evaluable patients in cohort A, and in two-thirds of patients in cohort B. No dose-limiting toxicities were observed for patients in cohort B. Of those with lung cancer, seven experienced stable disease and two had disease progression. In total, 83% of patients had treatment-related adverse events, the most common being diarrhea (37%), nausea, (37%), anorexia (30%), vomiting, (26%), and thrombocytopenia (22%).

“Future evaluations of birabresib need to consider intermittent scheduling to mitigate the potential toxicities of continuous dosing,” the authors concluded.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.